Target Name: FTSJ1
NCBI ID: G24140
Other Name(s): CDLIV | Putative tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase | 2'-O-ribose RNA methyltransferase TRM7 homolog | rRNA (uridine-2'-O-)-methyltransferase | XLID9 | TRM7_HUMAN | FtsJ RNA 2'-O

FTSJ1 as A Potential Drug Target for Various Diseases

FTSJ1 (CDLIV), a protein located on the surface of human immune cells, has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The FTSJ1 protein is a key component of the major histocompatibility complex (MHC), a protein complex that helps regulate immune responses. FTSJ1 is expressed in most tissues and cells of the body and is involved in the presentation of antigens to T cells, which are critical for cell-mediated immunity.

Studies have shown that FTSJ1 is involved in the regulation of immune cell function and is involved in the development of autoimmune diseases. For example, FTSJ1 has been shown to promote the development of T-cell lymphomas by promoting the activation and proliferation of T cells.

FTSJ1 has also been shown to be involved in the regulation of cancer cell growth and metastasis. For example, studies have shown that FTSJ1 is involved in the regulation of the growth and survival of cancer cells, and that inhibition of FTSJ1 has potential therapeutic implications for cancer treatment.

In addition to its role in immune and cancer regulation, FTSJ1 has also been shown to be involved in the development of neurodegenerative diseases. For example, studies have shown that FTSJ1 is involved in the regulation of the immune response and has been implicated in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

FTSJ1 has also been shown to be involved in the regulation of inflammation and has potential therapeutic implications for the treatment of inflammatory disorders. For example, studies have shown that FTSJ1 is involved in the regulation of inflammation and has been implicated in the development of inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease.

In conclusion, FTSJ1 is a protein that is involved in a wide range of biological processes and has potential as a drug target or biomarker for the treatment of various diseases. Further research is needed to fully understand the role of FTSJ1 in disease and to develop effective therapies for the treatment of FTSJ1-related disorders.

Protein Name: FtsJ RNA 2'-O-methyltransferase 1

Functions: Methylates the 2'-O-ribose of nucleotides at positions 32 and 34 of the tRNA anticodon loop of substrate tRNAs

More Common Targets

FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 | GABRB1 | GABRB2 | GABRB3 | GABRD | GABRE | GABRG1 | GABRG2